See other bills
under the
same topic
                                 SENATE AMENDED
        PRIOR PRINTER'S NOS. 1037, 2184, 3405         PRINTER'S NO. 4183

THE GENERAL ASSEMBLY OF PENNSYLVANIA


HOUSE BILL

No. 883 Session of 2007


        INTRODUCED BY KENNEY, CURRY, J. TAYLOR, BISHOP, SONNEY, MYERS,
           McILHATTAN, WATSON, REICHLEY, YOUNGBLOOD, SCAVELLO, O'NEILL,
           PETRONE, NAILOR, KOTIK, CAPPELLI, JOSEPHS, BAKER, CRUZ,
           FABRIZIO, COHEN, HENNESSEY, VULAKOVICH, WALKO, SOLOBAY,
           RUBLEY, GEIST, FREEMAN, CALTAGIRONE, JAMES, DENLINGER, HESS,
           GRUCELA, GOODMAN AND MELIO, MARCH 22, 2007

        SENATOR ARMSTRONG, APPROPRIATIONS, IN SENATE, RE-REPORTED AS
           AMENDED, JULY 2, 2008

                                     AN ACT

     1  Amending the act of September 9, 1965 (P.L.497, No.251),
     2     entitled "An act requiring physicians, hospitals and other
     3     institutions to administer or cause to be administered tests
     4     for phenylketonuria and other metabolic diseases upon infants
     5     in certain cases," further providing for newborn child
     6     screening and testing; and making editorial changes.

     7     The General Assembly of the Commonwealth of Pennsylvania
     8  hereby enacts as follows:
     9     Section 1.  The title of the act of September 9, 1965
    10  (P.L.497, No.251), known as the Newborn Child Testing Act, is
    11  amended to read:
    12                               AN ACT
    13  Requiring physicians, hospitals and other institutions to
    14     administer or cause to be administered tests for
    15     [phenylketonuria and other metabolic diseases] genetic,        <--
    16     metabolic, hormonal and functional conditions DISEASES upon    <--
    17     infants in certain cases.

     1     Section 2.  Section 3 of the act, added July 9, 1992
     2  (P.L.398, No.86), is amended to read:
     3     Section 3.  Newborn Child Screening and Follow-up Program.--
     4  (a)  In order to assist health care providers to determine
     5  whether treatment or other services are necessary to avert
     6  mental retardation, permanent disabilities or death, the
     7  department, with the approval of the [board] NEWBORN SCREENING    <--
     8  AND FOLLOW-UP TECHNICAL ADVISORY BOARD, shall establish a
     9  program providing for:
    10     (1)  The screening tests of newborn children for [diseases.]
    11  phenylketonuria (PKU), maple syrup urine disease (MSUD), sickle-  <--
    12  cell disease (hemoglobinopathies), galactosemia, congenital
    13  adrenal hyperplasia (CAH) and primary congenital
    14  hyperthyroidism. THE FOLLOWING DISEASES:                          <--
    15     (I)  PHENYLKETONURIA (PKU).
    16     (II)  MAPLE SYRUP URINE DISEASE (MSUD).
    17     (III)  SICKLE-CELL DISEASE (HEMOGLOBINOPATHIES).
    18     (IV)  GALACTOSEMIA.
    19     (V)  CONGENITAL ADRENAL HYPERPLASIA (CAH).
    20     (VI)  PRIMARY CONGENITAL HYPERTHYROIDISM HYPOTHYROIDISM.       <--
    21     (2)  Follow-up services relating to CASE MANAGEMENT,           <--
    22  REFERRALS, confirmatory screening, testing, assessment and        <--
    23  diagnosis of newborn children with abnormal [or inconclusive],    <--
    24  INCONCLUSIVE OR UNACCEPTABLE screening test results[.] for the
    25  following diseases:
    26     [(b)  The department, with the approval of the board, shall
    27  establish by regulation those diseases, in addition to
    28  phenylketonuria (PKU), maple syrup urine disease (MSUD) and
    29  sickle-cell disease (hemoglobinopathies, for which newborn
    30  children shall be tested and the methods for testing and
    20070H0883B4183                  - 2 -     

     1  disseminating test results.]
     2     (i)  Phenylketonuria (PKU).
     3     (ii)  Maple syrup urine disease (MSUD).
     4     (iii)  Sickle-cell disease (hemoglobinopathies).
     5     (iv)  Isovaleric acidemia/Isovalery-CoA dehydrogenase
     6  deficiency (IVA).
     7     (v)  Glutaric acidemia Type I/Glutaryl-CoA dehydrogenase
     8  deficiency Type I (GA I).
     9     (vi)  3-Hydroxy 3-methylglutaryl-CoA lyase deficiency (HMG).
    10     (vii)  Multiple carboxylase deficiency (MCD).
    11     (viii)  Methylmalonic acidemia (mutase deficiency) (MUT).
    12     (ix)  Methylmalonic acidemia (Cbl A,B).
    13     (x)  3-Methylcrontonyl-CoA carboxylase deficiency (3MCC).
    14     (xi)  Propionic acidemia/Propionyl-CoA carboxylase deficiency
    15  (PROP).
    16     (xii)  Beta-ketothiolase deficiency (BKT).
    17     (xiii)  Medium chain acyl-CoA dehydrogenase deficiency
    18  (MCAD).
    19     (xiv)  Very long-chain acyl-CoA dehydrogenase deficiency
    20  (VLCAD).
    21     (xv)  Long-chain L-3-OH acyl-CoA dehydrogenase deficiency
    22  (LCHAD).
    23     (xvi)  Trifunctional protein deficiency (TFP).
    24     (xvii)  Carnitine uptake defect (CUD).
    25     (xviii)  Homocystinuria (HCY).
    26     (xix)  Tyrosinemia type I (TYR I).
    27     (xx)  Argininosuccinic acidemia (ASA).
    28     (xxi)  Citrullinemia (CIT).
    29     (xxii)  Hb S/Beta-thalassemia (Hb S/Th).
    30     (xxiii)  Hb S/C disease (Hb S/C).
    20070H0883B4183                  - 3 -     

     1     (xxix) (XXIV)  Congenital hypothyroidism (HYPOTH).             <--
     2     (xxv)  Biotinidase deficiency (BIOT).
     3     (xxvi)  Congenital adrenal hyperplasia (CAH).
     4     (xxvii)  Galactosemia (GALT).
     5     (xxviii)  Cystic fibrosis (CF).
     6     (b.1)  All laboratories performing the screening tests for
     7  newborn children shall report the results to the department for
     8  follow-up activities.
     9     (c)  No screening test shall be performed if a parent or
    10  guardian dissents on the ground that the test conflicts with a
    11  religious belief or practice.
    12     (d)  The department, with the approval of the board NEWBORN    <--
    13  SCREENING AND FOLLOW-UP TECHNICAL ADVISORY BOARD, shall
    14  establish, by periodic publication in the Pennsylvania Bulletin,
    15  changes to the lists under subsection (a)(1) and (2) of those
    16  diseases for which newborn children shall be tested and for       <--
    17  which the department shall provide follow-up services. SCREENED   <--
    18  AND LABORATORY SCREENING RESULTS REPORTED.
    19     (e)  The department, with the approval of the board, shall     <--
    20  establish by regulation the methods for testing for those
    21  diseases listed under subsection (a)(1).
    22     (f) (E)  Notwithstanding any provisions of this act or the     <--
    23  act of April 23, 1956 (1955 P.L.1510, No.500), known as the
    24  "Disease Prevention and Control Law of 1955," to the contrary,
    25  test results and diagnoses based upon screening tests for the
    26  diseases listed in this section for newborn children shall be
    27  reported to the department. The department shall establish, by
    28  periodic publication in the Pennsylvania Bulletin, the method
    29  for reporting test results to the department.
    30     (g) (F)  Test results for genetic diseases listed in this      <--
    20070H0883B4183                  - 4 -     

     1  section, and any diseases subsequently added by the department
     2  under subsection (d), shall be subject to the confidentiality
     3  provisions of the "Disease Prevention and Control Law of 1955."
     4     Section 3.  This act shall take effect July 1, 2008 2009.      <--


















    C12L35MSP/20070H0883B4183        - 5 -